Novartis Raises Guidance Despite Trial Setbacks Hitting Profit

Novartis raises profit guidance despite $1.9 billion drug trial setback

Novartis increased its full-year core profit outlook for the third time in 2026, driven by growth of new medicines, but took a $1.9 billion write-down for neuromuscular drug candidate del-desiran following trial failure.